Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01902290) enrolled 210 people in the placebo group and 211 people in the brodalumab 210 mg group, for a total of 421 participants. The trial ran for 24 weeks and was primarily measuring changes in asthma control using a standardised questionnaire called the Asthma Control Questionnaire (ACQ), which scores asthma symptoms on a scale from 0 (fully controlled) to 6 (extremely poorly controlled). A lower score over time means fewer reported symptoms, and a drop of at least 0.50 points on this scale is considered meaningful. The reported data shows that both groups had lower ACQ scores at 24 weeks compared to where they started — meaning both groups reported fewer asthma symptoms on average. The placebo group's score dropped by 0.815 points, while the brodalumab group's score dropped by 0.865 points. For asthma flare-ups (episodes serious enough to need steroid treatment for at least three days), the placebo group had a reported rate of 0.57 flare-ups per person per year, while the brodalumab group had a reported rate of 0.81 flare-ups per person per year. Similar patterns were seen in a smaller subgroup of participants who were also taking a combination of two inhaler medicines. The reported data also shows small reductions in daily symptom diary scores and small improvements in a breathing test (measuring how much air a person can forcefully breathe out in one second) in both groups, with the brodalumab group going from 0.207 litres improvement in the placebo group to 0.237 litres in the brodalumab group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 30945020) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Asthma Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with asthma, and breathing tests at your screening visit show your lungs respond well to a bronchodilator (a medicine that opens the airways), with at least a 20% improvement.
- Your lung function test results at screening fall within a specific range — not too low and not too high (between 40% and 80% of what would be expected for someone your age and size).
- You are currently using an inhaled steroid medication (a common asthma preventer inhaler) at a dose within a specific range (confirm with trial site for your exact medication).
- You are still experiencing ongoing asthma symptoms, shown by a score of 1.5 or higher on a standard asthma control questionnaire at both your screening and baseline visits.
Who may not be able to join:
- You have a history of COPD (chronic obstructive pulmonary disease) or any other long-term lung condition besides asthma.
- You have a history of a fungal lung condition called allergic bronchopulmonary aspergillosis.
- You have had a respiratory infection (such as a chest or airway infection) within 4 weeks of your screening visit or within 1 week of your baseline visit.
- You have a known history of Crohn's disease.
- You have another significant medical condition or abnormal test results, as decided by the study team (confirm with trial site).
- You have previously been treated with any biologic medication that targets a protein called IL-17 (confirm with trial site).
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study.
- You are a woman who is unwilling to use highly effective contraception, unless you have been through menopause for at least 2 years or have had surgery that means you cannot become pregnant.
- You have severe depression or any thoughts or behaviours related to suicide, as measured by specific questionnaires used in the study.
- You have a history of a psychiatric condition or substance misuse that the study doctor believes could put your safety at risk.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.